Cerus Q3 2026 Net Loss Widens to $550,000

Bitget2026/11/02 21:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cerus’ third-quarter 2026 net loss attributable to the company widened year-over-year to $550,000.
Total revenue rose 6% year-over-year to $64 million, while product revenue increased 10% to $57.71 million.
Third-quarter operating cash flow climbed 58% year-over-year to $3 million.
Positive topline results from the Phase 3 RedeS trial marked a milestone for the INTERCEPT Blood System for red blood cells.
Full-year 2026 product revenue guidance remained $229 million to $231 million, including $23 million to $25 million from IFC.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerus Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202611021605BIZWIRE_USPR_____20261102_BW374071) on November 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cerus Q3 2026 Net Loss Widens to $550,000

You may also like

Crypto prices